3940 Trust Way
Hayward, CA 94545
United States
510 780 0819
https://benitec.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 16
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Jerel A. Banks M.D., Ph.D. | Executive Chairman & CEO | 848,07k | S.O. | 1975 |
Ms. Megan Joan Boston BComm, CA, Dip., GAICD | Executive Director | 439,17k | S.O. | 1972 |
Dr. Michael Graham | Head of Discovery & Founding Scientist | 126,34k | S.O. | S.O. |
Dr. Claudia Kloth | Senior Vice President of Manufacturing | S.O. | S.O. | S.O. |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
L’ISS Governance QualityScore de Benitec Biopharma Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..